David Kim to Humans
This is a "connection" page, showing publications David Kim has written about Humans.
Connection Strength
0.802
-
The role of simulation modelling in public health policy evaluation. Lancet Public Health. 2024 Mar; 9(3):e150-e151.
Score: 0.032
-
Development and Validation of the US Diabetes, Obesity, Cardiovascular Disease Microsimulation (DOC-M) Model: Health Disparity and Economic Impact Model. Med Decis Making. 2023 Oct-Nov; 43(7-8):930-948.
Score: 0.031
-
Accounting for Nonhealth and Future Costs in Cost-Effectiveness Analysis: Distributional Impacts of a US Cancer Prevention Strategy. Pharmacoeconomics. 2023 09; 41(9):1151-1164.
Score: 0.030
-
Developing Criteria for Health Economic Quality Evaluation Tool. Value Health. 2023 08; 26(8):1225-1234.
Score: 0.030
-
Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending. JAMA Netw Open. 2022 Nov 01; 5(11):e2243449.
Score: 0.029
-
State-Level Variation In Low-Value Care For Commercially Insured And Medicare Advantage Populations. Health Aff (Millwood). 2022 09; 41(9):1281-1290.
Score: 0.029
-
Effect of the 2012 US Preventive Services Task Force Recommendations on Prostate-Specific Antigen Screening in a Medicare Advantage Population. Med Care. 2022 12 01; 60(12):888-894.
Score: 0.029
-
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues. Value Health. 2022 08; 25(8):1298-1306.
Score: 0.028
-
The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. Value Health. 2022 08; 25(8):1336-1343.
Score: 0.028
-
How Does Cost-Effectiveness Analysis Inform Health Care Decisions? AMA J Ethics. 2021 08 01; 23(8):E639-647.
Score: 0.027
-
Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence? Value Health. 2021 11; 24(11):1586-1591.
Score: 0.027
-
An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. J Gen Intern Med. 2021 11; 36(11):3448-3455.
Score: 0.026
-
Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018. Pharmacoeconomics. 2020 10; 38(10):1135-1145.
Score: 0.025
-
Crisis into opportunity: can COVID-19 help set a path to improved health care efficiency? Am J Manag Care. 2020 09; 26(9):369-370.
Score: 0.025
-
Growth and capacity for cost-effectiveness analysis in Africa. Health Econ. 2020 08; 29(8):945-954.
Score: 0.025
-
Analyzing the Cost Effectiveness of Policy Responses for COVID-19: The Importance of Capturing Social Consequences. Med Decis Making. 2020 04; 40(3):251-253.
Score: 0.024
-
Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment. Pharmacoeconomics. 2020 02; 38(2):171-179.
Score: 0.024
-
Comparative Modeling to Inform Health Policy Decisions: A Step Forward. Ann Intern Med. 2019 12 03; 171(11):851-852.
Score: 0.024
-
Cost Effectiveness of Nutrition Policies on Processed Meat: Implications for Cancer Burden in the U.S. Am J Prev Med. 2019 11; 57(5):e143-e152.
Score: 0.024
-
Leveraging Cumulative Network Meta-analysis and Value of Information Analysis to Understand the Evolving Value of Medical Research. Med Decis Making. 2019 02; 39(2):119-129.
Score: 0.023
-
Targeted Incentive Programs For Lung Cancer Screening Can Improve Population Health And Economic Efficiency. Health Aff (Millwood). 2019 01; 38(1):60-67.
Score: 0.022
-
Economic Value of Greater Access to Bariatric Procedures for Patients With Severe Obesity and Diabetes. Med Care. 2018 07; 56(7):583-588.
Score: 0.022
-
Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery. Obes Surg. 2018 05; 28(5):1321-1328.
Score: 0.021
-
The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec; 17(6):615-623.
Score: 0.020
-
New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives. Med Decis Making. 2017 11; 37(8):930-941.
Score: 0.020
-
Estimating the Medical Care Costs of Obesity in the United States: Systematic Review, Meta-Analysis, and Empirical Analysis. Value Health. 2016 Jul-Aug; 19(5):602-13.
Score: 0.019
-
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence. Glob Public Health. 2015; 10(3):296-317.
Score: 0.017
-
Health and Economic Impacts of Implementing Produce Prescription Programs for Diabetes in the United States: A Microsimulation Study. J Am Heart Assoc. 2023 08; 12(15):e029215.
Score: 0.008
-
What is the cost-effectiveness of menu calorie labelling on reducing obesity-associated cancer burdens? An economic evaluation of a federal policy intervention among 235 million adults in the USA. BMJ Open. 2023 04 18; 13(4):e063614.
Score: 0.008
-
Medicare Part D Coverage of Antiobesity Medications - Challenges and Uncertainty Ahead. N Engl J Med. 2023 Mar 16; 388(11):961-963.
Score: 0.007
-
Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. J Am Coll Cardiol. 2022 07 12; 80(2):138-151.
Score: 0.007
-
Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. Vaccine. 2021 11 05; 39(46):6727-6734.
Score: 0.007
-
Cost-effectiveness Analysis of Nutrition Facts Added-Sugar Labeling and Obesity-Associated Cancer Rates in the US. JAMA Netw Open. 2021 04 01; 4(4):e217501.
Score: 0.007
-
Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses. Med Decis Making. 2021 04; 41(3):366-372.
Score: 0.006
-
Consideration Of Value-Based Pricing For Treatments And Vaccines Is Important, Even In The COVID-19 Pandemic. Health Aff (Millwood). 2021 01; 40(1):53-61.
Score: 0.006
-
Differential effects of cannabis exposure during early versus later adolescence on the expression of psychosis in homeless and precariously housed adults. Prog Neuropsychopharmacol Biol Psychiatry. 2021 03 02; 106:110084.
Score: 0.006
-
Measuring "Fearonomic Effects" in Valuing Therapies: An Application to COVID-19 in China. Value Health. 2020 11; 23(11):1405-1408.
Score: 0.006
-
Using QALYs versus DALYs to measure cost-effectiveness: How much does it matter? Int J Technol Assess Health Care. 2020 Apr; 36(2):96-103.
Score: 0.006
-
Are low and middle-income countries prioritising high-value healthcare interventions? BMJ Glob Health. 2020; 5(2):e001850.
Score: 0.006
-
Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. BMJ. 2020 01 28; 368:m141.
Score: 0.006
-
Variation in US private health plans' coverage of orphan drugs. Am J Manag Care. 2019 10; 25(10):508-512.
Score: 0.006
-
Future Directions for Cost-effectiveness Analyses in Health and Medicine. Med Decis Making. 2018 10; 38(7):767-777.
Score: 0.006
-
Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. Cancer Med. 2018 09; 7(9):4251-4260.
Score: 0.005
-
Specialty Drug Coverage Varies Across Commercial Health Plans In The US. Health Aff (Millwood). 2018 07; 37(7):1041-1047.
Score: 0.005
-
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value Health. 2018 07; 21(7):759-761.
Score: 0.005
-
Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology. 2013 Sep; 120(9):1835-42.
Score: 0.004
-
Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol. 2012 Apr; 130(4):497-505.
Score: 0.003